Piper Jaffray Upgrades Genomic Health, Downgrades BD | GenomeWeb

NEW YORK (GenomeWeb News) - Investment bank Piper Jaffray today upgraded the stock of Genomic Health while downgrading its rating on Becton Dickinson.

It upgraded Genomic Health from "neutral" to "overweight."

The Redwood City, Calif.-based pharmacogenomic test maker yesterday announced the worldwide launch of its Oncotype Dx colon cancer test. The 12-gene expression test has been developed for assessing risk of disease recurrence in patients that have stage II colon cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.